Vasoactive intestinal peptide: A neuropeptide with pleiotropic immune functions

Amino Acids

Volumn 45, Issue 1, 2013, Pages 25-39

  Delgado, Mario ^a   Ganea, Doina ^b  

^a INSTITUTO DE PARASITOLOGÍA Y BIOMEDICINA LÓPEZ NEYRA   (Spain)

^b TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Autoimmunity; Inflammation; Neuroinflammation; Neuropeptides neurotransmitters; Vasoactive intestinal peptide

Indexed keywords

CD4 ANTIGEN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; G PROTEIN COUPLED RECEPTOR; HIGH MOBILITY GROUP B1 PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON REGULATORY FACTOR 1; INTERLEUKIN 12; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 6; PATTERN RECOGNITION RECEPTOR; T LYMPHOCYTE RECEPTOR; TOLL LIKE RECEPTOR; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 1; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 2;

3' UNTRANSLATED REGION; ADAPTIVE IMMUNITY; AMINO TERMINAL SEQUENCE; ARTERY BLOOD FLOW; AUTOIMMUNE DISEASE; BINDING AFFINITY; BRONCHODILATATION; CARBOXY TERMINAL SEQUENCE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL CYCLE ARREST; CELL DIFFERENTIATION; CELL MIGRATION; CELL SURVIVAL; CHRONIC OBSTRUCTIVE LUNG DISEASE; DENDRITIC CELL; ENDOCYTOSIS; GASTROINTESTINAL MOTILITY; GENETIC POLYMORPHISM; GRAFT VERSUS HOST REACTION; HEART OUTPUT; HEPATITIS; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOSTIMULATION; INNATE IMMUNITY; INSULIN DEPENDENT DIABETES MELLITUS; LUNG ARTERY PRESSURE; LUNG LAVAGE; LUNG SARCOIDOSIS; MAST CELL DEGRANULATION; NONHUMAN; PANCREATITIS; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; REVIEW; SIGNAL TRANSDUCTION; SJOEGREN SYNDROME; SMOOTH MUSCLE CONTRACTION; TRANSCRIPTION REGULATION; UVEORETINITIS;

ANIMALS; AUTOIMMUNITY; CD4-POSITIVE T-LYMPHOCYTES; CENTRAL NERVOUS SYSTEM; DENDRITIC CELLS; HUMANS; INFLAMMATION; MACROPHAGES; MICE; NEUROIMMUNOMODULATION; PERIPHERAL NERVOUS SYSTEM; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE; SIGNAL TRANSDUCTION; VASOACTIVE INTESTINAL PEPTIDE;

EID: 84879218821     PISSN: 09394451     EISSN: 14382199     Source Type: Journal    
DOI: 10.1007/s00726-011-1184-8     Document Type: Review

References (124)

1. Abad C, Martinez C et al (2003) Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn's disease. Gastroenterology 124(4):961-971
2. Abad C, Juarranz Y et al (2005) cDNA array analysis of cytokines, chemokines, and receptors involved in the development of TNBS-induced colitis: homeostatic role of VIP. Inflamm Bowel Dis 11(7):674-684
3. Abad C, Tan YV et al (2010) Vasoactive intestinal peptide loss leads to impaired CNS parenchymal T-cell infiltration and resistance to experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA 107(45):19555-19560
4. Anderson P, Gonzalez-Rey E (2010) Vasoactive intestinal peptide induces cell cycle arrest and regulatory functions in human T cells at multiple levels. Mol Cell Biol 30(10):2537-2551
5. Arnalich F, de Miguel E et al (1994) Neuropeptides and interleukin-6 in human joint inflammation relationship between intraarticular substance P and interleukin-6 concentrations. Neurosci Lett 170(2):251-254
6. Arranz A, Juarranz Y et al (2008) VIP balances innate and adaptive immune responses induced by specific stimulation of TLR2 and TLR4. Peptides 29(6):948-956
7. Bangale Y, Karle S et al (2003) VIPase autoantibodies in Fas-defective mice and patients with autoimmune disease. FASEB J 17(6):628-635
8. Bellinger DL, Lorton D et al (1997) Vasoactive intestinal polypeptide (VIP) innervation of rat spleen, thymus, and lymph nodes. Peptides 18(8):1139-1149
9. Bovenschen HJ, van de Kerkhof PC et al (2011) Foxp3+ regulatory T Cells of psoriasis patients easily differentiate into IL-17A-producing cells and are found in lesional skin. J Invest Dermatol
10. Brandtzaeg P, Oktedalen O et al (1989) Elevated VIP and endotoxin plasma levels in human gram-negative septic shock. Regul Pept 24(1):37-44
11. Buckner JH (2010) Mechanisms of impaired regulation by CD4(+)CD25(+)FOXP3(+) regulatory T cells in human autoimmune diseases. Nat Rev Immunol 10(12):849-859
12. Camelo S, Lajavardi L et al (2009) Protective effect of intravitreal injection of vasoactive intestinal peptide-loaded liposomes on experimental autoimmune uveoretinitis. J Ocul Pharmacol Ther 25(1):9-21
13. Chen G, Hao J et al (2008) The therapeutic effect of vasoactive intestinal peptide on experimental arthritis is associated with CD4+ CD25+ T regulatory cells. Scand J Immunol 68(6):572-578
14. Chorny A, Delgado M (2008) Neuropeptides rescue mice from lethal sepsis by down-regulating secretion of the late-acting inflammatory mediator high mobility group box 1. Am J Pathol 172(5):1297-1307
15. Chorny A, Gonzalez-Rey E et al (2005) Vasoactive intestinal peptide induces regulatory dendritic cells with therapeutic effects on autoimmune disorders. Proc Natl Acad Sci USA 102(38):13562-13567
16. Chorny A, Gonzalez-Rey E et al (2006) Vasoactive intestinal peptide induces regulatory dendritic cells that prevent acute graft-versus-host disease while maintaining the graft-versus-tumor response. Blood 107(9):3787-3794
17. Delgado M (2002) Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit the MEKK1/MEK4/JNK signaling pathway in endotoxin-activated microglia. Biochem Biophys Res Commun 293(2):771-776
18. Delgado M, Ganea D (2000a) Inhibition of IFN-gamma-induced janus kinase-1-STAT1 activation in macrophages by vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. J Immunol 165(6):3051-3057
19. Delgado M, Ganea D (2000b) Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide inhibit the MEKK1/MEK4/JNK signaling pathway in LPS-stimulated macrophages. J Neuroimmunol 110(1-2):97-105
20. Delgado M, Ganea D (2001a) Cutting edge: is vasoactive intestinal peptide a type 2 cytokine? J Immunol 166(5):2907-2912
21. Delgado M, Ganea D (2001b) Inhibition of endotoxin-induced macrophage chemokine production by vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in vitro and in vivo. J Immunol 167(2):966-975
22. Delgado M, Ganea D (2001c) Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit nuclear factor-kappa B-dependent gene activation at multiple levels in the human monocytic cell line THP-1. J Biol Chem 276(1):369-380
23. Delgado M, Ganea D (2003a) Neuroprotective effect of vasoactive intestinal peptide (VIP) in a mouse model of Parkinson's disease by blocking microglial activation. FASEB J 17(8):944-946
24. Delgado M, Ganea D (2003b) Vasoactive intestinal peptide inhibits IL-8 production in human monocytes. Biochem Biophys Res Commun 301(4):825-832
25. Delgado M, Ganea D (2003c) Vasoactive intestinal peptide prevents activated microglia-induced neurodegeneration under inflammatory conditions: potential therapeutic role in brain trauma. FASEB J 17(13):1922-1924
26. Delgado M, Munoz-Elias EJ et al (1998) Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit tumor necrosis factor alpha transcriptional activation by regulating nuclear factor-kB and cAMP response element-binding protein/c-Jun. J Biol Chem 273(47):31427-31436
27. Delgado M, Martinez C et al (1999a) Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activation polypeptide (PACAP) protect mice from lethal endotoxemia through the inhibition of TNF-alpha and IL-6. J Immunol 162(2):1200-1205
28. Delgado M, Sun W et al (1999b) VIP and PACAP differentially regulate the costimulatory activity of resting and activated macrophages through the modulation of B7.1 and B7.2 expression. J Immunol 163(8):4213-4223
29. Delgado M, Abad C et al (2001) Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease. Nat Med 7(5):563-568
30. Delgado M, Jonakait GM et al (2002a) Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit chemokine production in activated microglia. Glia 39(2):148-161
31. Delgado M, Leceta J et al (2002b) Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide promote in vivo generation of memory Th2 cells. FASEB J 16(13):1844-1846
32. Delgado M, Gonzalez-Rey E et al (2004a) VIP/PACAP preferentially attract Th2 effectors through differential regulation of chemokine production by dendritic cells. Faseb J 18(12):1453-1455
33. Delgado M, Pozo D et al (2004b) The significance of vasoactive intestinal peptide in immunomodulation. Pharmacol Rev 56(2):249-290
34. Delgado M, Reduta A et al (2004c) VIP/PACAP oppositely affects immature and mature dendritic cell expression of CD80/CD86 and the stimulatory activity for CD4(+) T cells. J Leukoc Biol 75(6):1122-1130
35. Delgado M, Gonzalez-Rey E et al (2005) The neuropeptide vasoactive intestinal peptide generates tolerogenic dendritic cells. J Immunol 175(11):7311-7324
36. Delgado M, Robledo G et al (2008a) Genetic association of vasoactive intestinal peptide receptor with rheumatoid arthritis: altered expression and signal in immune cells. Arthr Rheum 58(4):1010-1019
37. Delgado M, Toscano MG et al (2008b) In vivo delivery of lentiviral vectors expressing vasoactive intestinal peptide complementary DNA as gene therapy for collagen-induced arthritis. Arthr Rheum 58(4):1026-1037
38. Delgado M, Varela N et al (2008c) Vasoactive intestinal peptide protects against beta-amyloid-induced neurodegeneration by inhibiting microglia activation at multiple levels. Glia 56(10):1091-1103
39. Delgado M, Anderson P et al (2009) Neuropeptides kill African trypanosomes by targeting intracellular compartments and inducing autophagic-like cell death. Cell Death Differ 16(3):406-416
40. Deng S, Xi Y et al (2010) Regulatory effect of vasoactive intestinal peptide on the balance of Treg and Th17 in collagen-induced arthritis. Cell Immunol 265(2):105-110
41. Dickinson T, Mitchell R et al (1999) The role of VIP/PACAP receptor subtypes in spinal somatosensory processing in rats with an experimental peripheral mononeuropathy. Neuropharmacology 38(1):167-180
42. Dickson L, Finlayson K (2009) VPAC and PAC receptors: from ligands to function. Pharmacol Ther 121(3):294-316
43. Dinsmore WW, Gingell C et al (1999) Treating men with predominantly nonpsychogenic erectile dysfunction with intracavernosal vasoactive intestinal polypeptide and phentolamine mesylate in a novel auto-injector system: a multicentre double-blind placebo-controlled study. BJU Int 83(3):274-279
44. El Karim IA, Linden GJ et al (2008) Antimicrobial activity of neuropeptides against a range of micro-organisms from skin, oral, respiratory and gastrointestinal tract sites. J Neuroimmunol 200(1-2):11-16
45. Fahrenkrug J (2010) VIP and PACAP. Results Probl Cell Differ 50:221-234
46. Favrais G, Couvineau A et al (2007) Involvement of VIP and PACAP in neonatal brain lesions generated by a combined excitotoxic/inflammatory challenge. Peptides 28(9):1727-1737
47. Fernandez-Martin A, Gonzalez-Rey E et al (2006) VIP prevents experimental multiple sclerosis by downregulating both inflammatory and autoimmune components of the disease. Ann NY Acad Sci 1070:276-281
48. Ferraccioli G, Zizzo G (2011) The potential role of Th17 in mediating the transition from acute to chronic autoimmune inflammation: rheumatoid arthritis as a model. Discov Med 11(60):413-424
49. Foster N, Lea SR et al (2007) Pivotal advance: vasoactive intestinal peptide inhibits up-regulation of human monocyte TLR2 and TLR4 by LPS and differentiation of monocytes to macrophages. J Leukoc Biol 81(4):893-903
50. Fraccaroli L, Alfieri J et al (2009) VIP modulates the pro-inflammatory maternal response, inducing tolerance to trophoblast cells. Br J Pharmacol 156(1):116-126
51. Fry DC, Madison VS et al (1989) Solution structure of an analogue of vasoactive intestinal peptide as determined by two-dimensional NMR and circular dichroism spectroscopies and constrained molecular dynamics. Biochemistry 28(6):2399-2409
52. Fujino S, Andoh A et al (2003) Increased expression of interleukin 17 in inflammatory bowel disease. Gut 52(1):65-70
53. Ganea D, Rodriguez R et al (2003) Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: players in innate and adaptive immunity. Cell Mol Biol (Noisy-le-grand) 49(2):127-142
54. Ganea D, Gonzalez-Rey E et al (2006) A novel mechanism for immunosuppression: from neuropeptides to regulatory T cells. J Neuroimmune Pharmacol 1(4):400-409
55. Goetzl EJ, Voice JK et al (2001) Enhanced delayed-type hypersensitivity and diminished immediate-type hypersensitivity in mice lacking the inducible VPAC(2) receptor for vasoactive intestinal peptide. Proc Natl Acad Sci USA 98(24):13854-13859
56. Gomariz RP, Arranz A et al (2005) Time-course expression of Toll-like receptors 2 and 4 in inflammatory bowel disease and homeostatic effect of VIP. J Leukoc Biol 78(2):491-502
57. Gonzalez-Rey E, Delgado M (2006) Therapeutic treatment of experimental colitis with regulatory dendritic cells generated with vasoactive intestinal peptide. Gastroenterology 131(6):1799-1811
58. Gonzalez-Rey E, Delgado M (2007) Anti-inflammatory neuropeptide receptors: new therapeutic targets for immune disorders? Trends Pharmacol Sci 28(9):482-491
59. Gonzalez-Rey E, Chorny A et al (2006a) Vasoactive intestinal peptide generates human tolerogenic dendritic cells that induce CD4 and CD8 regulatory T cells. Blood 107(9):3632-3638
60. Gonzalez-Rey E, Fernandez-Martin A et al (2006b) Vasoactive intestinal peptide induces CD4+, CD25+ T regulatory cells with therapeutic effect in collagen-induced arthritis. Arthr Rheum 54(3):864-876
61. Gonzalez-Rey E, Fernandez-Martin A et al (2006c) Therapeutic effect of vasoactive intestinal peptide on experimental autoimmune encephalomyelitis: down-regulation of inflammatory and autoimmune responses. Am J Pathol 168(4):1179-1188
62. Gonzalez-Rey E, Anderson P et al (2007) Emerging roles of vasoactive intestinal peptide: a new approach for autoimmune therapy. Ann Rheum Dis 66(Suppl 3):iii70-iii76
63. Gonzalez-Rey E, Ganea D et al (2010) Neuropeptides: keeping the balance between pathogen immunity and immune tolerance. Curr Opin Pharmacol 10(4):473-481
64. Gozes I, Divinsky I et al (2003) From vasoactive intestinal peptide (VIP) through activity-dependent neuroprotective protein (ADNP) to NAP: a view of neuroprotection and cell division. J Mol Neurosci 20(3):315-322
65. Guerrero J, Prieto J et al (1981) Interaction of vasoactive intestinal peptide with human blood mononuclear cells. Mol Cell Endocrinol 21(2):151-160
66. Gutierrez-Canas I, Juarranz Y et al (2006) VIP down-regulates TLR4 expression and TLR4-mediated chemokine production in human rheumatoid synovial fibroblasts. Rheumatology (Oxford) 45(5):527-532
67. Hamidi SA, Szema AM et al (2006) Clues to VIP function from knockout mice. Ann NY Acad Sci 1070:5-9
68. Harmar AJ, Arimura A et al (1998) International union of pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. Pharmacol Rev 50(2):265-270
69. Henning RJ, Sawmiller DR (2001) Vasoactive intestinal peptide: cardiovascular effects. Cardiovasc Res 49(1):27-37
70. Herrera JL, Gonzalez-Rey E et al (2009) Toll-like receptor stimulation differentially regulates vasoactive intestinal peptide type 2 receptor in macrophages. J Cell Mol Med 13(9B):3209-3217
71. Hill JM (2007) Vasoactive intestinal peptide in neurodevelopmental disorders: therapeutic potential. Curr Pharm Des 13(11):1079-1089
72. Jiang X, Jing H et al (2002) VIP and PACAP down-regulate CXCL10 (IP-10) and up-regulate CCL22 (MDC) in spleen cells. J Neuroimmunol 133(1-2):81-94
73. Jimeno R, Gomariz RP et al (2010) New insights into the role of VIP on the ratio of T-cell subsets during the development of autoimmune diabetes. Immunol Cell Biol 88(7):734-745
74. Jones KB, Mollano AV et al (2004) Bone and brain: a review of neural, hormonal, and musculoskeletal connections. Iowa Orthop J 24:123-132
75. Juarranz Y, Gutierrez-Canas I et al (2008) Differential expression of vasoactive intestinal peptide and its functional receptors in human osteoarthritic and rheumatoid synovial fibroblasts. Arthr Rheum 58(4):1086-1095
76. Kebir H, Kreymborg K et al (2007) Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat Med 13(10):1173-1175
77. Keino H, Kezuka T et al (2004) Prevention of experimental autoimmune uveoretinitis by vasoactive intestinal peptide. Arch Ophthalmol 122(8):1179-1184
78. Kim WK, Kan Y et al (2000) Vasoactive intestinal peptide and pituitary adenylyl cyclase-activating polypeptide inhibit tumor necrosis factor-alpha production in injured spinal cord and in activated microglia via a cAMP-dependent pathway. J Neurosci 20(10):3622-3630
79. Kojima M, Ito T et al (2005) VIP attenuation of the severity of experimental pancreatitis is due to VPAC1 receptor-mediated inhibition of cytokine production. Pancreas 30(1):62-70
80. Korkmaz OT, Tuncel N et al (2010) Vasoactive intestinal peptide (VIP) treatment of Parkinsonian rats increases thalamic gamma-aminobutyric acid (GABA) levels and alters the release of nerve growth factor (NGF) by mast cells. J Mol Neurosci 41(2):278-287
81. Langer I, Robberecht P (2007) Molecular mechanisms involved in vasoactive intestinal peptide receptor activation and regulation: current knowledge, similarities to and differences from the A family of G-protein-coupled receptors. Biochem Soc Trans 35(Pt 4):724-728
82. Lauenstein HD, Quarcoo D et al (2010) Pituitary adenylate cyclase-activating peptide receptor 1 mediates anti-inflammatory effects in allergic airway inflammation in mice. Clin Exp Allergy 41(4):592-601
83. Leuchte HH, Baezner C et al (2008) Inhalation of vasoactive intestinal peptide in pulmonary hypertension. Eur Respir J 32(5):1289-1294
84. Li JM, Southerland L et al (2011) Absence of vasoactive intestinal peptide expression in hematopoietic cells enhances Th1 polarization and antiviral immunity in mice. J Immunol 187(2):1057-1065
85. Liu L, Yen JH et al (2007) A novel VIP signaling pathway in T cells cAMP- > protein tyrosine phosphatase (SHP-2?)- > JAK2/STAT4- > Th1 differentiation. Peptides 28(9):1814-1824
86. Lodde BM, Mineshiba F et al (2006) Effect of human vasoactive intestinal peptide gene transfer in a murine model of Sjogren's syndrome. Ann Rheum Dis 65(2):195-200
87. Luo Q, Wang Y et al (2009) Vasoactive intestinal peptide attenuates concanavalin A-mediated liver injury. Eur J Pharmacol 607(1-3):226-233
88. Maldonado RA, von Andrian UH (2010) How tolerogenic dendritic cells induce regulatory T cells. Adv Immunol 108:111-165
89. Martinez C, Delgado M et al (1998) VIP and PACAP enhance IL-6 release and mRNA levels in resting peritoneal macrophages: in vitro and in vivo studies. J Neuroimmunol 85(2):155-167
90. Martinez C, Abad C et al (2002) Anti-inflammatory role in septic shock of pituitary adenylate cyclase-activating polypeptide receptor. Proc Natl Acad Sci USA 99(2):1053-1058
91. Masmoudi-Kouki O, Gandolfo P et al (2007) Role of PACAP and VIP in astroglial functions. Peptides 28(9):1753-1760
92. Mazzocchi G, Rebuffat P et al (1998) Vasoactive intestinal peptide stimulates rat adrenal glucocorticoid secretion, through an ACTH receptor-dependent activation of the adenylate cyclase signaling pathway. Horm Metab Res 30(5):241-243
93. Moody TW, Ito T et al (2011) VIP and PACAP: recent insights into their functions/roles in physiology and disease from molecular and genetic studies. Curr Opin Endocrinol Diabetes Obes 18(1):61-67
94. O'Dorisio MS, Hermina NS et al (1981) Vasoactive intestinal polypeptide modulation of lymphocyte adenylate cyclase. J Immunol 127(6):2551-2554
95. Onoue S, Misaka S et al (2010) Inhalable powder formulation of vasoactive intestinal peptide derivative, [R15, 20, 21, L17]-VIP-GRR, attenuated neutrophilic airway inflammation in cigarette smoke-exposed rats. Eur J Pharm Sci 41(3-4):508-514
96. Paladini F, Cocco E et al (2008) A functional polymorphism of the vasoactive intestinal peptide receptor 1 gene correlates with the presence of HLA-B 2705 in Sardinia. Genes Immun 9(8):659-667
97. Palermo MS, Vermeulen ME et al (1996) Human antibody-dependent cellular cytotoxicity mediated by interferon gamma-activated neutrophils is impaired by vasoactive intestinal peptide. J Neuroimmunol 69(1-2):123-128
98. Passemard S, El Ghouzzi V et al (2011a) VIP blockade leads to microcephaly in mice via disruption of Mcph1-Chk1 signaling. J Clin Invest
99. Passemard S, Sokolowska P et al (2011b) VIP-induced neuroprotection of the developing brain. Curr Pharm Des 17(10):1036-1039
100. Pedrera C, Lucas M et al (1994) Receptor-independent mechanisms are involved in the priming of neutrophil's oxidase by vasoactive intestinal peptide. Regul Pept 54(2-3):505-511
101. Petkov V, Mosgoeller W et al (2003) Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. J Clin Invest 111(9):1339-1346
102. Piggins HD, Cutler DJ (2003) The roles of vasoactive intestinal polypeptide in the mammalian circadian clock. J Endocrinol 177(1):7-15
103. Pozo D, Anderson P et al (2009) Induction of alloantigen-specific human T regulatory cells by vasoactive intestinal peptide. J Immunol 183(7):4346-4359
104. Prasse A, Zissel G et al (2010) Inhaled vasoactive intestinal peptide exerts immunoregulatory effects in sarcoidosis. Am J Respir Crit Care Med 182(4):540-548
105. Reynolds AD, Stone DK et al (2010) Regulatory T cells attenuate Th17 cell-mediated nigrostriatal dopaminergic neurodegeneration in a model of Parkinson's disease. J Immunol 184(5):2261-2271
106. Said SI, Mutt V (1970) Polypeptide with broad biological activity: isolation from small intestine. Science 169(951):1217-1218
107. Said SI, Rosenberg RN (1976) Vasoactive intestinal polypeptide: abundant immunoreactivity in neural cell lines and normal nervous tissue. Science 192(4242):907-908
108. Sakaguchi S, Miyara M et al (2010) FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol 10(7):490-500
109. Samarasinghe AE, Hoselton SA et al (2011) The absence of VPAC2 leads to aberrant antibody production in Aspergillus fumigatus sensitized and challenged mice. Peptides 32(1):131-137
110. Sharma V, Delgado M et al (2006) Granzyme B, a new player in activation-induced cell death, is down-regulated by vasoactive intestinal peptide in Th2 but not Th1 effectors. J Immunol 176(1):97-110
111. Smalley SG, Barrow PA et al (2009) Immunomodulation of innate immune responses by vasoactive intestinal peptide (VIP): its therapeutic potential in inflammatory disease. Clin Exp Immunol 157(2):225-234
112. Snoek SA, Borensztajn KS et al (2010) Neuropeptide receptors in intestinal disease: physiology and therapeutic potential. Curr Pharm Des 16(9):1091-1105
113. Sun W, Hong J et al (2006) Altered expression of vasoactive intestinal peptide receptors in T lymphocytes and aberrant Th1 immunity in multiple sclerosis. Int Immunol 18(12):1691-1700
114. Szema AM, Hamidi SA et al (2006) Mice lacking the VIP gene show airway hyperresponsiveness and airway inflammation, partially reversible by VIP. Am J Physiol Lung Cell Mol Physiol 291(5):L880-L886
115. Tan YV, Abad C et al (2009) Pituitary adenylyl cyclase-activating polypeptide is an intrinsic regulator of Treg abundance and protects against experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA 106(6):2012-2017
116. Toscano MG, Delgado M et al (2010) Dendritic cells transduced with lentiviral vectors expressing VIP differentiate into VIP-secreting tolerogenic-like DCs. Mol Ther 18(5):1035-1045
117. Vaudry D, Falluel-Morel A et al (2009) Pituitary adenylate cyclase-activating polypeptide and its receptors: 20 years after the discovery. Pharmacol Rev 61(3):283-357
118. Voice JK, Grinninger C et al (2003) Roles of vasoactive intestinal peptide (VIP) in the expression of different immune phenotypes by wild-type mice and T cell-targeted type II VIP receptor transgenic mice. J Immunol 170(1):308-314
119. Voice J, Donnelly S et al (2004) c-Maf and JunB mediation of Th2 differentiation induced by the type 2 G protein-coupled receptor (VPAC2) for vasoactive intestinal peptide. J Immunol 172(12):7289-7296
120. Vosko AM, Schroeder A et al (2007) Vasoactive intestinal peptide and the mammalian circadian system. Gen Comp Endocrinol 152(2-3):165-175
121. Wang HY, Jiang XM et al (2000) The neuropeptides VIP and PACAP inhibit IL-2 transcription by decreasing c-Jun and increasing JunB expression in T cells. J Neuroimmunol 104(1):68-78
122. Winzell MS, Ahren B (2007) Role of VIP and PACAP in islet function. Peptides 28(9):1805-1813
123. Yadav M, Rosenbaum J et al (2008) Cutting edge: vasoactive intestinal peptide (VIP) induces differentiation of Th17 cells with a distinctive cytokine profile. J Immunol 180(5):2772-2776
124. Yu R, Zhang H et al (2011) Anti-hyperglycemic, antioxidant and anti-inflammatory effects of VIP and a VPAC1 agonist on streptozotocin-induced diabetic mice. Peptides 32(2):216-222